Trial reportThe Journal of pediatrics2010
Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.
Trial report in The Journal of pediatrics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inhaled nitric oxide for respiratory failure in preterm infants.The Cochrane database of systematic reviews · 2017Pooled it
- Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial.JAMA pediatrics · 2017Trial
- Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study.Pediatric research · 2012Trial
- Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age.Acta paediatrica (Oslo, Norway : 1992) · 2011Trial
- Clinical and environmental risk factors for childhood developmental disabilities: A narrative review (1990-2025).World journal of clinical pediatrics · 2026Review
- Hydrogen sulfide alleviates hyperoxia effects on mitochondria in human developing airway smooth muscle.JCI insight · 2026Article
- Exogenous hydrogen sulfide attenuates hyperoxia effects on neonatal mouse airways.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Efficacy of inhaled nitric oxide in preterm infants ≤ 34 weeks: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Review
- Oxygen and mechanical stretch in the developing lung: risk factors for neonatal and pediatric lung disease.Frontiers in medicine · 2023Review
- Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.Neuropharmacology · 2016Review
- Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant.Seminars in perinatology · 2016Review
- Nitric oxide in paediatric respiratory disorders: novel interventions to address associated vascular phenomena?Therapeutic advances in cardiovascular disease · 2016Review
- cAMP-mediated secretion of brain-derived neurotrophic factor in developing airway smooth muscle.Biochimica et biophysica acta · 2015Article
- Brain Injury in the Preterm Infant: New Horizons for Pathogenesis and Prevention.Pediatric neurology · 2015Review
- Stochastic process for white matter injury detection in preterm neonates.NeuroImage. Clinical · 2015Article
- Brain injury in premature neonates: A primary cerebral dysmaturation disorder?Annals of neurology · 2014Article
- Cerebral white and gray matter injury in newborns: new insights into pathophysiology and management.Clinics in perinatology · 2014Review
- Can nitric oxide-based therapy prevent bronchopulmonary dysplasia?Clinics in perinatology · 2012Review
- Nitric oxide counteracts the hyperoxia-induced proliferation and proinflammatory responses of mouse astrocytes.Free radical biology & medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveIn a randomized multi-center trial, we demonstrated that inhaled nitric oxide begun between 7 and 21 days and given for 24 days significantly increased survival without bronchopulmonary dysplasia (BPD) in ventilated premature infants weighing <1250 g. Because some preventative BPD treatments are associated with neurodevelopmental impairment, we designed a follow-up study to assess the safety of nitric oxide. STUDY
designOur hypothesis was that inhaled nitric oxide would not increase neurodevelopmental impairment compared with placebo. We prospectively evaluated neurodevelopmental and growth outcomes at 24 months postmenstrual age in 477 of 535 surviving infants (89%) enrolled in the trial.
resultsIn the treated group, 109 of 243 children (45%) had neurodevelopmental impairment (moderate or severe cerebral palsy, bilateral blindness, bilateral hearing loss, or score <70 on the Bayley Scales II), compared with 114 of 234 (49%) in the placebo group (relative risk, 0.92; 95% CI, 0.75-1.12; P = .39). No differences on any subcomponent of neurodevelopmental impairment or growth variables were found between inhaled nitric oxide or placebo.
conclusionsInhaled nitric oxide improved survival free of BPD, with no adverse neurodevelopmental effects at 2 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.